Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

被引：21

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
]}

Myint, Zin W. ^{[3
]}

Iacovelli, Roberto ^{[4
]}

Pichler, Martin ^{[5
]}

Basso, Umberto ^{[6
]}

Kopecky, Jindrich ^{[7
]}

Kucharz, Jakub ^{[8
]}

Buti, Sebastiano ^{[9
]}

Rizzo, Mimma ^{[10
]}

Galli, Luca ^{[11
]}

Buettner, Thomas ^{[12
]}

De Giorgi, Ugo ^{[13
]}

Kanesvaran, Ravindran ^{[14
]}

Fiala, Ondrej ^{[15
]}

Grande, Enrique ^{[16
]}

Zucali, Paolo Andrea ^{[17
,18
]}

Fornarini, Giuseppe ^{[19
]}

Bourlon, Maria T. ^{[20
]}

Scagliarini, Sarah ^{[21
]}

Molina-Cerrillo, Javier ^{[22
]}

Aurilio, Gaetano ^{[23
]}

Matrana, Marc R. ^{[24
]}

Pichler, Renate ^{[25
]}

Cattrini, Carlo ^{[26
]}

Buechler, Tomas ^{[27
]}

Seront, Emmanuel ^{[28
]}

Calabro, Fabio ^{[29
]}

Pinto, Alvaro ^{[30
]}

Berardi, Rossana ^{[31
]}

Zgura, Anca ^{[32
]}

Mammone, Giulia ^{[33
]}

Ansari, Jawaher ^{[34
]}

Atzori, Francesco ^{[35
]}

Chiari, Rita ^{[36
]}

Bamias, Aristotelis ^{[37
]}

Caffo, Orazio ^{[38
]}

Procopio, Giuseppe ^{[39
,40
]}

Bassanelli, Maria ^{[41
]}

Merler, Sara ^{[42
]}

Messina, Carlo ^{[43
]}

Kueronya, Zsofia ^{[44
]}

Mosca, Alessandra ^{[45
]}

Bhuva, Dipen ^{[46
]}

Vau, Nuno ^{[47
]}

Incorvaia, Lorena ^{[48
]}

Rebuzzi, Sara Elena ^{[49
,50
]}

Roviello, Giandomenico ^{[51
]}

Zabalza, Ignacio Ortego ^{[16
]}

Rizzo, Alessandro ^{[52
]}

机构：

[1] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol Med, Rome, Italy

[5] Med Univ Graz, Dept Internal Med, Div Oncol, Augenbruggerplatz 15, A-8010 Graz, Austria

[6] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Oncol Unit 3, Padua, Italy

[7] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove, Czech Republic

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Uro Oncol, Warsaw, Poland

[9] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[10] AOU Consorziale Policlin Bari, Div Med Oncol, Piazza G Cesare 11, I-70124 Bari, Italy

[11] Univ Hosp Pisa, Oncol Unit 2, I-56126 Pisa, Italy

[12] Univ Hosp Bonn UKB, Dept Urol, D-53127 Bonn, Germany

[13] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Meldola, Italy

[14] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[15] Charles Univ Prague, Univ Hosp Pilsen, Fac Med, Dept Oncol & Radiotherapeut, Plzen, Czech Republic

[16] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[17] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Milan, Italy

[18] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[19] IRCCS Osped Policlin San Martino, Genoa, Italy

[20] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Oncol Dept, Mexico City, Mexico

[21] Azienda Osped Rilievo Nazl Cardarelli Napoli, UOC Oncol, Naples, Italy

[22] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[23] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[24] Ochsner Med Ctr, Dept Internal Med, Hematol Oncol, New Orleans, LA USA

[25] Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria

[26] Maggiore Car Univ Hosp, Dept Med Oncol, I-28100 Novara, Italy

[27] Charles Univ Prague, Thomayer Univ Hosp, Fac Med 1, Dept Oncol, Prague 14059, Czech Republic

[28] Ctr Hospitalier Jolimont, Dept Med Oncol, Haine St Paul, Haine Saint Paul, Belgium

[29] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[30] La Paz Univ Hosp, Med Oncol Dept, Madrid, Spain

[31] Univ Politecn Marche, Dept Med Oncol, AOU Ospedali Riuniti Marche, Ancona, Italy

[32] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[33] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Viale Regina Elena 324, I-00185 Rome, Italy

[34] Tawam Hosp, Med Oncol, Al Ain, U Arab Emirates

[35] Azienda Osped Univ Cagliari, Unita Oncol Med, Cagliari, Italy

[36] Azienda Osped Ospedali Riuniti Marche Nord, UOC Oncol, Tuscany, Italy

[37] Natl & Kapodistrian Univ Athens, ATTIKON Univ Hosp, Sch Med, Propaedeut Dept Internal Med 2, Athens, Greece

[38] Santa Chiara Hosp, Med Oncol Unit, Trento, Italy

[39] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Med, Milan, Italy

[40] Osped Maggiore Cremona, Oncol Med, Cremona, Italy

[41] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[42] Univ Verona, Verona Univ Hosp Trust, Dept Med, Sect Oncol,Sch Med, Verona, Italy

[43] ARNAS Civ, Oncol Unit, Palermo, Italy

[44] Natl Inst Oncol, Dept Genitourinary Med Oncol & Clin Pharmacol, Budapest, Hungary

[45] IRCCS FPO, Candiolo Canc Inst, Oncol, I-10060 Turin, Italy

[46] Army Hosp Res & Referral, Dept Med Oncol, New Delhi, India

[47] Champalimaud Clin Ctr, Urol Oncol, P-1400038 Lisbon, Portugal

[48] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[49] Osped San Paolo, Med Oncol, I-17100 Savona, Italy

[50] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

来源：

TARGETED ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

CYTOREDUCTIVE NEPHRECTOMY; SUNITINIB; CANCER;

D O I：

10.1007/s11523-023-00978-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.

引用

页码：559 / 570

页数：12

共 50 条

[31] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
Shah, Neil J.
Sura, Sneha D.
Shinde, Reshma
Shi, Junxin
Singhal, Puneet
Perini, Rodolfo F.
Motzer, Robert J.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
[32] Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
Taniguchi, Tomoki
Iinuma, Koji
Kawada, Kei
Ishida, Takashi
Takagi, Kimiaki
Tomioka, Masayuki
Kawase, Makoto
Kawase, Kota
Nakane, Keita
Tobisawa, Yuki
Koie, Takuya
CURRENT ONCOLOGY, 2024, 31 (12) : 7914 - 7923
[33] Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
Sazuka, Tomokazu
Matsushita, Yuto
Sato, Hiroaki
Osawa, Takahiro
Hinata, Nobuyuki
Hatakeyama, Shingo
Numakura, Kazuyuki
Ueda, Kosuke
Kimura, Takahiro
Takahashi, Masayuki
Tanaka, Hajime
Kawasaki, Yoshihide
Kurahashi, Toshifumi
Kato, Takuma
Fujita, Kazutoshi
Miyake, Makito
Kojima, Takahiro
Kitamura, Hiroshi
Miyake, Hideaki
Ichikawa, Tomohiko
SCIENTIFIC REPORTS, 2023, 13 (01):
[34] Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
Fiala, Ondrej
Buti, Sebastiano
Fujita, Kazutoshi
de Liano, Alfonso Gomez
Fukuokaya, Wataru
Kimura, Takahiro
Yanagisawa, Takafumi
Giannatempo, Patrizia
Angel, Martin
Mennitto, Alessia
Molina-Cerrillo, Javier
Bourlon, Maria T.
Soares, Andrey
Takeshita, Hideki
Calabro, Fabio
Ortega, Cinzia
Kucharz, Jakub
Milella, Michele
Seront, Emmanuel
Park, Se Hoon
Tural, Deniz
Benedetti, Giovanni
Urun, Yuksel
Battelli, Nicola
Melichar, Bohuslav
Poprach, Alexandr
Buchler, Tomas
Kopecky, Jindrich
Conteduca, Vincenza
Monteiro, Fernando Sabino Marques
Massari, Francesco
Gupta, Shilpa
Santoni, Matteo
CLINICAL & EXPERIMENTAL METASTASIS, 2025, 42 (02)
[35] Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma
Harada, Ken-ichi
Miyake, Hideaki
Furukawa, Junya
Fujimoto, Naohiro
Fujisawa, Masato
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (08) : 816 - 822
[36] Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes
Venugopal, Balaji
Pillai, Manon
Powles, Thomas
Savage, Philip
Michael, Agnieszka
Fife, Kate
Klair, Bhupinder
Perrot, Valerie
Szabados, Bernadett
CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 94 - +
[37] Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
van Laar, S. A.
Gombert-Handoko, K. B.
Groenwold, R. H. H.
van der Hulle, T.
Visser, L. E.
Houtsma, D.
Guchelaar, H. J.
Zwaveling, J.
FRONTIERS IN PHARMACOLOGY, 2022, 13
[38] Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan
Inamoto, Teruo
Azuma, Haruhito
Tatsugami, Katsunori
Oya, Mototsugu
Adachi, Masatoshi
Okayama, Yutaka
Sunaya, Toshiyuki
Akaza, Hideyuki
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (07) : 615 - 623
[39] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
Zakharia, Yousef
Thomaidou, Despina
Li, Benjamin
Siu, Gordon
Levin, Rebecca
Vlahiotis, Anna
Rao, Dharanija
Zanotti, Giovanni
FRONTIERS IN ONCOLOGY, 2022, 12
[40] Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database
Maroun, Rana
Fleury, Laetitia
Nachbaur, Gaelle
Maunoury, Franck
Vanhille, Jean-Louis
Durand-Zaleski, Isabelle
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1755 - 1762

← 1 2 3 4 5 →